Leadership

READDI team

READDI brings together the world’s brightest scientific, business and policy minds to meet the critical challenge of pandemic preparedness.

James Rosen

James Rosen

CEO and Director

Full Profile

Ralph S. Baric

Ralph S. Baric

Co-founder and Scientific Adviser

Full Profile

Fletcher Fairey

Fletcher Fairey

Executive Vice President of Business

Full Profile

Mark Heise

Mark Heise

Co-founder and Scientific Adviser

Full Profile

Nathaniel Moorman

Nathaniel Moorman

Co-founder and Scientific Adviser

Full Profile

Logan Ward

Logan Ward

Director of Communications

Full Profile

Board of Directors

John Bamforth

John Bamforth

Executive Director, Eshelman Innovation, UNC-Chapel Hill

Full Profile

Richard Burr

Richard Burr

Principal Policy Advisor/Chair, Health Policy Strategic Consulting practice, DLA Piper
Former U.S. Senator, North Carolina

Full Profile

J. Christopher Clemens

J. Christopher Clemens

Provost and Chief Academic Officer, UNC-Chapel Hill

Full Profile

Laurent Fraisse

Laurent Fraisse

Research & Development Director, Drugs for Neglected Diseases Initiative

Full Profile

Andy Johns

Andy Johns

Senior Associate Vice Chancellor for Research, UNC-Chapel Hill

Full Profile

Perrin W. Jones

Perrin W. Jones

Anesthesiologist and partner, East Carolina Anesthesia Associates
Board of Trustees member, UNC-Chapel Hill

Full Profile

Nathan Knuffman

Nathan Knuffman

Vice Chancellor for Finance and Operations and Chief Financial Officer, UNC-Chapel Hill

Full Profile

Lydia Ogden

Lydia Ogden

Global Public Health R&D Policy and External Engagement Leader, Johnson & Johnson

Full Profile

Tom Shanahan

Tom Shanahan

Chief Legal Officer, UNC Health

Full Profile

Barbara Stephenson

Barbara Stephenson

Vice Provost for Global Affairs and Chief Global Officer, UNC-Chapel Hill

Full Profile

Brad Wilken

Brad Wilken

Deputy Director for Business Development and Licensing, Bill & Melinda Gates Foundation

Full Profile

The purpose of READDI is to harness all the smart people toward the specific objective of making medicines to prevent the next pandemic.”